Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers

OTTMAR LEISS AND KLAUS VON BERGMANN

From the Department of Medicine, University of Bonn, Bonn, Federal Republic of Germany

SUMMARY The effect of Rowachol (200 mg tid), an essential oil preparation, on biliary lipid secretion and serum lipids was measured in six healthy male volunteers before and after four weeks of treatment. Biliary cholesterol and phospholipid secretion increased significantly from 113±36 (SD) μmol/h to 155±52 μmol/h (<0.05) and from 409±145 μmol/h to 587±185 μmol/h (<0.05), respectively. Bile acid secretion increased from 1519±662 μmol/h to 2287±1175 μmol/h (>0.05 and >0.10). This marked increase in biliary lipid secretion was not followed by a change in molar composition of biliary lipids and lithogenicity of bile. Serum cholesterol and triglycerides declined from 4.9 mmol/l to 4.1 mmol/l (<0.05) and from 1.2 mmol/l to 0.9 mmol/l (<0.05) respectively. The ratio of high-density-lipoprotein cholesterol to total cholesterol increased from 0.22 to 0.31 (<0.05). Although it has been shown previously that Rowachol could dissolve cholesterol gall stones the present results indicate that Rowachol alone has only weak litholytic properties, at least in normal volunteers, but might have several advantages when combined with chenodeoxycholic or ursodeoxycholic acid.

Chronic administration of either chenodeoxycholic acid or ursodeoxycholic acid has been shown to reduce lithogenicity of bile thereby promoting dissolution of cholesterol gall stones. Recently, another agent, Rowachol, has been shown to be effective in dissolving gall stones and biliary tract stones. This essential oil preparation containing the mono- and bicyclic monoterpenes menthol (32% w/v), pinene (17% w/v), menthone (6% w/v), borneol (5% w/v), camphene (5% w/v) and cineole (2% w/v) in olive oil (ROWA-Wagner KG, 5060 Bergisch-Gladbach 1, FRG) has been used as a choleretic and therapeutic agent for biliary tract diseases in Europe for more than 25 years. Whereas chenodeoxycholic acid and ursodeoxycholic acid reduce the lithogenicity of bile by decreasing biliary lipid output of cholesterol the mechanism by which Rowachol effect biliary lipid metabolism has not been elucidated. The purpose of the present study was to examine the effects of Rowachol on biliary lipid secretion and serum lipid concentration in normal volunteers.

Methods

EXPERIMENTAL DESIGN
Six healthy young male volunteers were studied as outpatients at the Metabolic Unit, Department of Medicine, University of Bonn. The study was conducted in accordance with the principles of the Helsinki declaration and informed consent was obtained from each subject. None of the subjects had evidence of gastrointestinal disease and routine liver function tests were normal. Age, body weight, and height are given in Table 1. During the study period each subject was on his usual diet and no changes in body weight occurred.

Biliary lipid secretion rates were measured before

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (yr)</th>
<th>Body weight (kg)</th>
<th>Height (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>23</td>
<td>84</td>
<td>184</td>
</tr>
<tr>
<td>2</td>
<td>22</td>
<td>76</td>
<td>192</td>
</tr>
<tr>
<td>3</td>
<td>25</td>
<td>77</td>
<td>190</td>
</tr>
<tr>
<td>4</td>
<td>26</td>
<td>74</td>
<td>187</td>
</tr>
<tr>
<td>5</td>
<td>25</td>
<td>70</td>
<td>176</td>
</tr>
<tr>
<td>6</td>
<td>26</td>
<td>69</td>
<td>180</td>
</tr>
</tbody>
</table>
and after four weeks of administration of Rowachol (200 mg tid). Blood was taken after an overnight fast before and after two and four weeks of administration of Rowachol. Serum was separated and stored at −20°C until serum lipid analysis.

**EXPERIMENTAL PROCEDURE**

Biliary lipid secretion was measured by the intestinal perfusion technique described by Grundy and Metzger. The evening before the study the subjects were admitted to the Metabolic Ward where they swallowed a triple lumen tube. After an overnight fast the tube was positioned with two proximal outlets adjacent to the ampulla of Vater and a third outlet 10 cm distally just beyond the ligamentum of Treitz. A liquid formula diet (142 cal/kg/h) containing 36% of calories as fat (70% in the form of lard), 16% as protein and 48% as carbohydrates (Nutrodrip, Wander GmbH, 6522 Osthofen, FRG) together with beta-sitosterol (22.5 mg/h) as a non-absorbable marker were infused constantly through the most proximal outlet. After allowing four hours for gall bladder contraction and stabilisation of hepatic bile secretion hourly samples were obtained for the following six hours from the second proximal and the distal outlet by continuous aspiration. During the regimen of Rowachol administration 400 mg of this terpene mixture was given in the morning of the study before liquid formula infusion was started.

Storage of the proximal samples and separation of bile acids from cholesterol and phospholipids were performed according to the method used in the National Cooperative Gallstone Study. Ten millilitres of the distal samples were added to ethanol. In every proximal and distal sample, cholesterol and beta-sitosterol were measured by gas liquid chromatography as trimethylsilylethers using 5-alpha-cholestan as internal standard. In every proximal sample bile acids were determined enzymatically and phospholipids were measured by the method of Bartlett. Hourly outputs of cholesterol, bile acids and phospholipids were then calculated according to equations given by Grundy and Metzger along with correction factors for cholesterol content of the perfused formula. Biliary lipid composition was expressed as molar per cent for each lipid component according to Admirand and Small and per cent saturation was calculated by the criteria of Carey and Small assuming a total lipid content of hepatic bile of 5 g/dl.

Individual bile acids were determined in every proximal sample by gas liquid chromatography. The conjugated bile acids were deconjugated enzymatically (cholylglycin hydrolase; Sigma Chemicals Co, St. Louis, Mo. (20)) and solvolised.

After methylation and derivatisation to their trimethylsilylethers the individual bile acids were separated on a fused silica capillary column (SP 2100, 25 m, ID 0.20–0.21 mm, Hewlett Packard, Palo Alto, CA) using an automatic injection system (7671 A Automatic Sampler, Hewlett Packard).

**SERUM LIPIDS**

Total lipids, cholesterol, phospholipids and triglycerides were determined by the micromethod of Egge et al. High-density-lipoprotein cholesterol was determined in the supernatant after precipitation of apolipoprotein-B containing lipoproteins with dextran sulphate/magnesium chloride using a micromethod described recently. Previous studies by one of us have shown that high-density-lipoprotein-cholesterol determined by this micromethod was in good agreement with high-density-lipoprotein-cholesterol determined by ultracentrifugation according to Havel et al.

**STATISTICAL ANALYSIS**

The results are expressed as mean±SD. Results between control period and Rowachol administration were compared with the Wilcoxon's signed rank test.

**Results**

**EFFECT OF ROWACHOL ON BILIARY LIPID SECRETION**

Biliary lipid outputs during control period and after administration of Rowachol are given in Table 2. Biliary cholesterol secretion averaged 113 μmol/h during control period and increased after administration of Rowachol by 37% to 155 μmol/h (p<0.05). Biliary secretion of phospholipids averaged 409 μmol/h during control period and increased significantly by 36% to 587 μmol/h during Rowachol treatment (p<0.05). The average increase in bile acid secretion from 1519 μmol/h to 2287 μmol/h (51%) was not significant (p>0.05 and <0.10). Administration of Rowachol had no effect on molar composition of cholesterol, bile acids, phospholipids or the lithogenic index (Table 3). Molar ratios of cholesterol to bile acids, cholesterol to phospholipids and phospholipids to bile acids during the control period averaged 0.09±0.03, 0.29±0.09 and 0.28±0.07, respectively. Administration of Rowachol did not alter these ratios (0.08±0.03, 0.27±0.05 and 0.29±0.09, respectively). No change in the molar composition of individual bile acids was observed during administration of Rowachol, except for lithocholic acid, the smallest fraction, which increased (Table 4).
Table 2  Biliary lipid secretion rates in normal volunteers during control period and after four weeks of treatment with Rowachol (200 mg tid)

<table>
<thead>
<tr>
<th>Subject</th>
<th>Cholesterol (μmol/h±SD)</th>
<th>Phospholipids (μmol/h±SD)</th>
<th>Bile acids (μmol/h±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CO</td>
<td>ROW</td>
<td>CO</td>
</tr>
<tr>
<td>1</td>
<td>151±16</td>
<td>133±43</td>
<td>579±92</td>
</tr>
<tr>
<td>2</td>
<td>90±14</td>
<td>141±22</td>
<td>253±65</td>
</tr>
<tr>
<td>3</td>
<td>122±17</td>
<td>155±18</td>
<td>590±146</td>
</tr>
<tr>
<td>4</td>
<td>57±8</td>
<td>119±43</td>
<td>334±149</td>
</tr>
<tr>
<td>5</td>
<td>151±5</td>
<td>255±41</td>
<td>405±34</td>
</tr>
<tr>
<td>6</td>
<td>109±23</td>
<td>125±22</td>
<td>295±59</td>
</tr>
<tr>
<td>±±SD</td>
<td>113±36</td>
<td>155±51†</td>
<td>409±145</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1519±662</td>
</tr>
</tbody>
</table>

Abbreviations: CO = Control period; ROW = Rowachol period.
* Values for each subject represent the average for 6 determinations during the steady state period of formula infusion.
† p between 0-05 and 0-10.
‡ p between 0-05 and 0-10.

Discussion

Effects of Rowachol on serum lipids

Mean total lipids, cholesterol, triglycerides and phospholipids before, after two and four weeks of treatment with Rowachol are presented in Table 5. A significant reduction of triglyceride concentration in serum was observed after two and four weeks. Phospholipids and total lipids showed a significant decrease after four weeks. High-density-lipoprotein-cholesterol increased slightly (14%) after four weeks, and with the parallel small but not significant decrease in total cholesterol the ratio of high-density-lipoprotein-cholesterol to total cholesterol increased significantly (p<0-05).

EFFECTS OF ROWACHOL ON BILIARY LIPID SECRETION

The results of this study in normal volunteers show that administration of Rowachol (200 mg tid) for four weeks increases biliary outputs of bile acids, phospholipids, and cholesterol to almost the same rate extending previous studies in animals and preliminary results in patients with indwelling T-tube after cholecystectomy. The obtained secretion rates of biliary lipids are in the same range as in other groups of normal volunteers published previously as well as studied recently in our department. (In 20 healthy volunteers the hourly secretion rates of cholesterol, phospholipids, bile acids and the LI of hepatic bile averaged 120±19, 420±140, 1776±277 μmol/h and 0.96±0.26, respectively). Whether the present results obtained in normal volunteers might be extrapolated to patients with cholesterol gall stones has to be elucidated. How Rowachol promote this parallel increase in output of all biliary lipids remains unclear. Other drugs for treatment of cholesterol gall stone disease or hyperlipidemia do not induce such remarkable effects on biliary lipid secretion.

Table 3  Biliary lipid composition and lithogenic index of stimulated hepatic bile in normal volunteers during control period and after 4 weeks of treatment with Rowachol (200 mg tid)

<table>
<thead>
<tr>
<th>Subject</th>
<th>Cholesterol (molar %) (mean±SD*)</th>
<th>Phospholipids (molar %) (mean±SD*)</th>
<th>Bile acids (molar %) (mean±SD*)</th>
<th>Lithogenic Index (CS) (mean±SD*)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CO</td>
<td>ROW</td>
<td>CO</td>
<td>ROW</td>
</tr>
<tr>
<td>1</td>
<td>6-9±0-7</td>
<td>5-6±1-3</td>
<td>26-2±1-5</td>
<td>24-0±6-5</td>
</tr>
<tr>
<td>2</td>
<td>7-2±0-7</td>
<td>4-0±0-3</td>
<td>20-3±5-2</td>
<td>18-7±2-1</td>
</tr>
<tr>
<td>3</td>
<td>3-7±0-6</td>
<td>4-9±0-8</td>
<td>17-5±1-7</td>
<td>17-4±1-1</td>
</tr>
<tr>
<td>4</td>
<td>3-2±0-2</td>
<td>7-1±1-3</td>
<td>18-1±5-1</td>
<td>28-2±4-7</td>
</tr>
<tr>
<td>5</td>
<td>6-6±0-4</td>
<td>4-7±0-5</td>
<td>17-8±0-5</td>
<td>16-3±1-8</td>
</tr>
<tr>
<td>6</td>
<td>8-5±0-1</td>
<td>7-5±0-7</td>
<td>23-0±2-3</td>
<td>20-3±1-4</td>
</tr>
<tr>
<td>±±SD</td>
<td>6-0±2-1</td>
<td>5-6±1-4</td>
<td>20-5±3-5</td>
<td>20-8±4-5</td>
</tr>
</tbody>
</table>

Abbreviations: CO = Control period; ROW = Rowachol period; CS = Lithogenic Index calculated according to Carey and Small assuming a total lipid content of hepatic bile of 5 g/dl.
* Values for each subject represent the average for 6 determinations during the steady state period of formula infusion.
Rowachol and biliary lipid secretion

Table 4  Mean molar per cent of individual bile acids in bile in normal volunteers during control period and after four weeks of treatment with Rowachol (200 mg tid)

<table>
<thead>
<tr>
<th>Subject</th>
<th>LICA (molar %)</th>
<th>DCA (molar %)</th>
<th>CDCA (molar %)</th>
<th>CA (molar %)</th>
<th>UDCA (molar %)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CO</td>
<td>ROW</td>
<td>CO</td>
<td>ROW</td>
<td>CO</td>
</tr>
<tr>
<td>1</td>
<td>0.29</td>
<td>1.09</td>
<td>19.95</td>
<td>31.58</td>
<td>39.24</td>
</tr>
<tr>
<td>2</td>
<td>0.52</td>
<td>0.72</td>
<td>24.03</td>
<td>24.16</td>
<td>41.15</td>
</tr>
<tr>
<td>3</td>
<td>0.12</td>
<td>0.98</td>
<td>20.80</td>
<td>19.45</td>
<td>43.37</td>
</tr>
<tr>
<td>4</td>
<td>0.98</td>
<td>1.03</td>
<td>25.79</td>
<td>23.01</td>
<td>53.12</td>
</tr>
<tr>
<td>5</td>
<td>0.85</td>
<td>1.86</td>
<td>15.20</td>
<td>19.42</td>
<td>43.92</td>
</tr>
<tr>
<td>6</td>
<td>1.26</td>
<td>1.17</td>
<td>17.32</td>
<td>12.29</td>
<td>49.62</td>
</tr>
<tr>
<td>Mean ±SD</td>
<td>0.67</td>
<td>1.14</td>
<td>20.51</td>
<td>21.65</td>
<td>45.07</td>
</tr>
</tbody>
</table>

Abbreviations: LICA = lithocholic acid; DCA = deoxycholic acid; CDCA = chenodeoxycholic acid; CA = cholic acid; UDCA = ursodeoxycholic acid; CO = Control period; ROW = Rowachol period.

* Values for each subject represent the average for 6 determinations during the steady state period of formula infusion.
† Significantly different from CO (p<0.05).

The observed increase of biliary lipid output had no consistent effect on lithogenicity of hepatic bile. Molar ratios of cholesterol to bile acids, cholesterol to phospholipids and phospholipids to bile acids were not changed after Rowachol administration indicating that this terpene mixture did not alter the coupling of cholesterol or phospholipids to bile acids. As shown in Table 3, however, in four of the volunteers with a lithogenic index greater than 0.9 treatment with Rowachol slightly decreased the lithogenic index. These results are comparable with those of acute studies by Doran et al. With the same dose regimen these investigators found a significant decrease in cholesterol saturation of gall bladder bile obtained by needle aspiration in patients at the time of abdominal surgery.

EFFECTS OF ROWACHOL ADMINISTRATION ON SERUM LIPIDS

The beneficial effects of Rowachol on serum lipids support previous studies in patients with cholestasis and hyperlipoproteinaemia. The significant increase in the absolute values of high-density-lipoprotein-cholesterol during treatment with this terpene preparation observed by Bell et al. and Hordinsky and Hordinsky could not be confirmed in the present study, probably because normal lipidemic volunteers were studied during shorter treatment periods. When expressed as relative values, however, (ratio of high-density-lipoprotein-cholesterol to total cholesterol) the change from 0.22 to 0.31 was statistically significant (p<0.05). The beneficial effect of this terpene preparation on serum lipids might be of advantage for treatment of hyperlipidemic patients with increased risk factors for gall stone formation as common lipid lowering drugs like clofibrate, bezafibrate, and probably nicotinic acid increase lithogenicity of bile.

MECHANISM OF CHOLESTEROL GALL STONE DISSOLUTION BY ROWACHOL

The mechanism whereby Rowachol induces cholesterol gall stone dissolution is not clear. In the present study the lithogenic index in normal volunteers was not influenced consistently by Rowachol, in contrast with known effects of chenodeoxycholic acid and ursodeoxycholic acid. Thus, other effects after Rowachol administration seems also to be important for gall stone dissolution. In addition to the relative concentration of bile acids, phospholipids and cholesterol total lipid content of bile is another important determinant of cholesterol solubility. In the present study Rowachol increased total lipid output and total lipid concentration of duodenal content (0.67 g/l versus 0.87 g/l; p<0.05). This observation is in line with results of

Table 5  Mean serum lipids during control period and after 2 weeks and 4 weeks of administration of Rowachol (200 mg tid)

<table>
<thead>
<tr>
<th></th>
<th>CO (mean±SD)</th>
<th>2 weeks (mean±SD)</th>
<th>4 weeks (mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total lipids (g/l)</td>
<td>6.53±0.91</td>
<td>6.40±0.69</td>
<td>5.22±1.14*</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.22±0.29</td>
<td>0.95±0.22</td>
<td>0.87±0.29*</td>
</tr>
<tr>
<td>Phospholipids (mmol/l)</td>
<td>2.89±0.92</td>
<td>2.09±0.68</td>
<td>2.09±0.62*</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4.91±0.38</td>
<td>4.89±0.63</td>
<td>4.07±0.64</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.09±0.14</td>
<td>1.38±0.32</td>
<td>1.25±0.23</td>
</tr>
<tr>
<td>HDL-cholesterol</td>
<td>0.22±0.04</td>
<td>0.28±0.06*</td>
<td>0.31±0.05*</td>
</tr>
</tbody>
</table>

Abbreviations: CO = Control period; ROW = Rowachol period.
* Significantly different from CO (p<0.05).
Bell et al\(^9\) who show that Rowachol (100 mg tid) given to gall stone patients three months before cholecystectomy increased biliary lipid concentration significantly. Thus, the increase in biliary lipid concentration produced by Rowachol might contribute to the litholytic properties of this mixture of plant monoterpens. Furthermore, several of the terpenes – for example, menthol, menthophe and pinene – are excellent cholesterol solvents in \textit{vitro}.

The structurally related terpene, d-limonene, has been recently used as an agent for dissolving common duct scenes.\(^{40}\) Therefore, physicochemical properties of some of the individual components of Rowachol may also contribute to the choledolitholytic effects. Although, administration of Rowachol alone might dissolve gall stone in some patients,\(^4\)\(^5\)\(^41\)\(^42\) a combination with chenodeoxycholic acid or ursodeoxycholic acid might be of advantage for several reasons. First, the dissolution rates of gall stone may be accelerated, as already shown by Ellis \textit{et al}.\(^{41}\)\(^42\) Second, the dose of chenodeoxycholic acid or ursodeoxycholic acid might be lowered, decreasing the cost of medical gall stone dissolution. And third, the lipid lowering effect of this essential oil preparation may prevent the increase of LDL-cholesterol observed by the National Cooperative Gallstone Study during chenodeoxycholic acid therapy.\(^{43}\) A combination of Rowachol with ursodeoxycholic acid might be even more effective in reducing lithogenicity of bile. Preliminary results from our department in a randomised study indicate that low dose ursodeoxycholic acid (250 mg/day) combined with Rowachol decreased the lithogenic index of super-saturated gall bladder bile in patients with gall stones and/or hyperlipoproteinemia more (from 1:88 to 1:02; p<0.01, n=6) than low dose chenodeoxycholic acid (250 mg/day) plus Rowachol (from 1:32 to 1:33; n=6) or ursodeoxycholic acid alone (1000 mg/day; from 1:00 to 0:77; p<0.05, hepatic bile, n=6).

The work was supported by grant Le 385/1 of the Deutsche Forschungsgemeinschaft, Bonn, FRG. The authors thank Mrs P Pitters and G Westphal and Mr S Weiner for excellent technical assistance.

References

3 Makino J, Shinizaki K, Nakagawa K, Yoshino K. Dissolution of cholesterol gallstones by ursodeoxy-

Rowachol and biliary lipid secretion


Effect of Rowachol on biliary lipid secretion and serum lipids in normal volunteers.

O Leiss and K von Bergmann

*Gut* 1985 26: 32-37
doi: 10.1136/gut.26.1.32

Updated information and services can be found at:
http://gut.bmj.com/content/26/1/32

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/